Bionor Pharma ASA is proceeding with development of its experimental HIV vaccine even after it failed to keep patients off antiviral drugs in an early trial. Buoyed by subsequent findings that the ...

Feb 24 (Reuters) - Bionor Pharma ASA : * Said on Tuesday third and final assay for measuring latent HIV reservoir size, the primary endpoint in the REDUC Part B trial, supports that the ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES Bionor Pharma ASA completes extraordinary ...

The conclusive data provide a basis for further HIV trials, offering Bionor three main pathways to market: o Re-vaccination to reduce the viral set point further - aiming at a 'functional cure' o ...

Stocks Analysis by Edison covering: . Read Edison 's latest article on Investing.com ...

Bionor Pharma ASA, the Norwegian developer of an experimental AIDS treatment, said the injection lowered viral levels in patients’ blood and helped some of them stay off daily pills for more ...

(Oslo, Norway, 20 June 2016) Bionor Pharma ASA (BIONOR.OL) announced today, that the Board contemplates to launch a private placement of up to about NOK 70 million to be conducted within the end of ...

(Oslo, Norway, 12 August 2016) Referring to previous stock exchange announcements as of 20 June 2016 and 30 June 2016, the Board of Directors of Bionor today announced that the size of the ...

The peer-reviewed and highly recognized journal The Lancet HIV has accepted the results of the REDUC Part B trial for publication (Oslo, Norway, 9 June 2016) Bionor Pharma ASA (Bionor ...

* Contemplates to launch private placement of up to about 70 million Norwegian crowns ($8.4 million) to be conducted within end of this month ...

Bionor Pharma ASA releases earnings for Q1 on May 26. Analysts predict earnings per share of NOK 0.872. Go here to watch Bionor Pharma ASA stock price in real-time on Markets Insider. Bionor ...

BIONOR PHARMA ASA INTERIM FINANCIAL REPORT 1 JANUARY - 31 MARCH 2016 UNAUDITED 11 MAY 2016 HIGHLIGHTS Q1 2016 In the first quarter of 2016, Bionor continued its preparation of the BIOSKILL trial ...